Open Access. Powered by Scholars. Published by Universities.®
Articles 1 - 2 of 2
Full-Text Articles in Life Sciences
Overcoming Tcf4-Driven Bcr Signaling In Diffuse Large B-Cell Lymphoma, Keenan Hartert
Overcoming Tcf4-Driven Bcr Signaling In Diffuse Large B-Cell Lymphoma, Keenan Hartert
Theses & Dissertations
Diffuse Large B-cell Lymphoma (DLBCL) is the most common subtype of lymphoma. Despite a cure rate of 40% with standard R-CHOP therapy, patients that refract or relapse are subject to a dismal prognosis. Cases of DLBCL can be classified by their molecular expression phenotype, with the GCB-like subtype aligning with the profile of a germinal center B-cell and the ABC-like subtype aligning to that of an activated B-cell. Aggressive disease is often characterized by high levels of B-cell Receptor (BCR) signaling. This pathway engages downstream kinases responsible for stimulating proliferation and survival that play a key role under the normal …
Sprouty 2: A Novel Attenuator Of B Cell Receptor And Mapk Signaling In Chronic Lymphocytic Leukemia, Ashima Shukla
Sprouty 2: A Novel Attenuator Of B Cell Receptor And Mapk Signaling In Chronic Lymphocytic Leukemia, Ashima Shukla
Theses & Dissertations
Clinical heterogeneity is a major barrier to effective treatment of Chronic Lymphocytic Leukemia (CLL). Emerging evidence suggests that constitutive activation of various signaling pathways plays a role in the heterogeneous clinical outcome of CLL patients. MAPK-Erk signaling represents one such pathway with a demonstrated role in CLL pathogenesis. In this study, we have investigated the role of Sprouty2 (SPRY2) as a negative regulator of receptor and non-receptor tyrosine kinase signaling in the pathogenesis of CLL. We show that SPRY2 expression is significantly decreased in CLL cells, particularly from poor prognosis patients compared to those from good prognosis patients. Over-expression of …